Advertisement
CLDX vs OVID
Which Stock Would AI Choose? Celldex Therapeutics (CLDX) vs. Ovid Therapeutics (OVID) Stock Comparison
Key Takeaways
- Celldex Therapeutics (CLDX) is a late-stage immunology biotech with positive Phase 3 data, while Ovid Therapeutics (OVID) is an earlier-stage neurology developer with strong recent momentum.
- CLDX carries a larger market capitalization and a de-risked lead program, whereas OVID trades at a small-cap valuation with a broad "Strong Buy" analyst consensus.
- Recent relative performance diverges sharply: CLDX has pulled back in recent weeks, while OVID has posted substantial gains over the past year.
- Tickeron AI Verdict: CLDX is favored for its more advanced pipeline, realized Phase 3 catalysts, and comparatively stable market positioning.
- For more detail, explore CLDX Major News and CLDX Today's Price Move, plus OVID Major News and OVID Today's Price Move.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison evaluates two clinical-stage biopharmaceutical companies operating in different therapeutic areas: CLDX (Celldex Therapeutics), which develops antibody therapies for inflammatory, allergic, and autoimmune conditions, and OVID (Ovid Therapeutics), which focuses on small-molecule medicines for brain and neurological disorders. Both stocks appeal to investors who follow biotechnology catalysts, clinical trial readouts, and analyst sentiment. Their differing development stages, market capitalizations, and recent price behavior make this a useful comparison for traders seeking relative performance insight and market positioning in the volatile biotech sector.
CLDX Overview and Recent Performance
Celldex Therapeutics (CLDX) develops therapeutic antibodies targeting severe inflammatory, allergic, and autoimmune diseases, with a mast-cell-focused pipeline anchored by its lead candidate barzolvolimab. In recent weeks, the company reported positive Phase 3 topline results for barzolvolimab in chronic spontaneous urticaria (CSU), meeting its primary endpoint and key secondary endpoints across two pivotal trials. This represented a significant de-risking event for the pipeline, with management indicating plans for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) in 2027.
Despite the favorable Phase 3 data, the stock has experienced volatility, trading lower over the past one to three months. Sentiment has also been tempered by a separate Phase 2 setback in prurigo nodularis (a chronic skin condition), where barzolvolimab missed its primary and secondary endpoints, prompting discontinuation of development in that indication. A planned transition of the company's chief financial officer (CFO) has added to near-term uncertainty. Analysts nonetheless maintain a "Strong Buy" consensus with price targets well above recent trading levels.
OVID Overview and Recent Performance
Ovid Therapeutics (OVID) is a biopharmaceutical company developing small-molecule medicines for brain disorders linked to neural hyperexcitability, including epilepsies and seizure-related neurological conditions. Its pipeline features OV329, a next-generation inhibitor targeting drug-resistant focal onset seizures, and KCC2 activators OV350 and OV4071 for neurological and psychiatric disorders. Recent months brought positive Phase 1 data for OV329, Phase 1 clearance for OV4071, and a strengthened executive leadership team, including a new chief financial officer.
The company has extended its cash runway into 2028 and was added to the S&P Biotechnology Select Industry Index, supporting its broader visibility. OVID has delivered substantial gains over the past year, and analyst sentiment is notably bullish, with a "Strong Buy" consensus and price targets implying significant upside from current levels. However, the stock remains early-stage and volatile, and it carries elevated short interest, reflecting continued skepticism about execution and clinical milestones.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each defined by its own trading style, strategy, timeframe, performance statistics, and target universe. Because not every bot suits every market regime, Tickeron curates only the strongest and most relevant performers into its Trending AI Robots section. This curated list highlights bots demonstrating favorable recent performance and alignment with current market conditions, making it a practical starting point for traders comparing automated strategies. Whether you are evaluating individual stocks like CLDX and OVID or scanning broader opportunities, the Trending AI Robots page offers a focused view of the strategies currently standing out. Explore the Trending AI Robots page to see which automated approaches are adapting to today's market.
Head-to-Head Comparison
The two companies occupy distinct positions within biotechnology. CLDX operates in immunology with a lead asset that has already demonstrated positive Phase 3 results, giving it a later-stage, more de-risked profile and a larger market capitalization of roughly $2.3 billion. Its principal risks center on regulatory timing, long-term safety monitoring, and pipeline diversification after the prurigo nodularis setback.
OVID operates in neurology with a market capitalization near $500 million and a largely early-stage pipeline, meaning its value remains tied to future clinical readouts rather than already-validated registrational data. Its trade-offs include higher volatility, elevated short interest, and execution risk, balanced by a longer cash runway, index inclusion, and stronger recent share-price momentum. In terms of market positioning, CLDX offers relative stability through confirmed clinical milestones, while OVID offers higher-risk, higher-momentum exposure to neurological catalysts.
Tickeron AI Verdict
Based on observable factors such as pipeline maturity, trend consistency, realized catalysts, and relative positioning, Tickeron's AI would currently favor CLDX (Celldex Therapeutics) over OVID (Ovid Therapeutics). The preference reflects CLDX's confirmed Phase 3 success, a later-stage development timeline, and a broader analyst "Strong Buy" consensus, which together suggest a comparatively more stable risk profile. While OVID demonstrates stronger recent momentum and an extended cash runway, its earlier-stage pipeline and higher volatility introduce greater uncertainty. This assessment is probabilistic and grounded in current market positioning rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and OVID is a Hold.
Momentum Indicator for CLDX turns positive, indicating new upward trend
CLDX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 74 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Oscillator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CLDX just turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Following a +10.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for CLDX moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CLDX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OVID's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OVID turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 48 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CLDX | OVID | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 57 | 37 | |
P/E GROWTH RATING 1..100 | 25 | 76 | |
SEASONALITY SCORE 1..100 | 39 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OVID's Valuation (17) in the Pharmaceuticals Major industry is significantly better than the same rating for CLDX (99) in the Biotechnology industry. This means that OVID’s stock grew significantly faster than CLDX’s over the last 12 months.
OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLDX (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to CLDX’s over the last 12 months.
OVID's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as CLDX (98) in the Biotechnology industry. This means that OVID’s stock grew similarly to CLDX’s over the last 12 months.
OVID's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as CLDX (57) in the Biotechnology industry. This means that OVID’s stock grew similarly to CLDX’s over the last 12 months.
CLDX's P/E Growth Rating (25) in the Biotechnology industry is somewhat better than the same rating for OVID (76) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew somewhat faster than OVID’s over the last 12 months.
| CLDX | OVID | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 82% |
| Advances ODDS (%) | 3 days ago 77% | 8 days ago 77% |
| Declines ODDS (%) | 21 days ago 78% | 10 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLDX’s FA Score shows that 1 FA rating(s) are green while OVID’s FA Score has 1 green FA rating(s).
- CLDX’s FA Score: 1 green, 4 red.
- OVID’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLDX’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 6 bullish TA indicator(s).
- CLDX’s TA Score: 4 bullish, 5 bearish.
- OVID’s TA Score: 6 bullish, 4 bearish.
Price Growth
CLDX (@Biotechnology) experienced а +3.16% price change this week, while OVID (@Biotechnology) price change was +16.67% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CLDX is expected to report earnings on Mar 01, 2027.
OVID is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OVID and
Correlation & Price change
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with CLDX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | -1.75% | ||
| CLDX - OVID | 42% Loosely correlated | -1.89% | ||
| SLDB - OVID | 42% Loosely correlated | +2.14% | ||
| SANA - OVID | 40% Loosely correlated | -1.42% | ||
| VIR - OVID | 40% Loosely correlated | -3.63% | ||
| CADL - OVID | 40% Loosely correlated | -1.48% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CBOT | 21.57 | 0.76 | +3.63% |
| Corgi Robots & Humanoids ETF (CBOT) | |||
| GAA | 34.47 | -0.24 | -0.69% |
| Cambria Global Asset Allocation ETF (GAA) | |||
| PTH | 59.35 | -0.57 | -0.95% |
| Invesco Dorsey Wright Healthcare Momentum ETF (PTH) | |||
| TNA | 57.69 | -1.21 | -2.05% |
| Direxion Daily Small Cap Bull 3X ETF (TNA) | |||
| QETH | 20.43 | -0.70 | -3.31% |
| Invesco Galaxy Ethereum ETF (QETH) | |||